| P2093 | author name string | Kehmia Titanji | |
| P2860 | cites work | Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. | Q53207044 |
| | Ovariectomy-induced bone loss occurs independently of B cells. | Q53510692 |
| | Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study | Q57902645 |
| | Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy | Q73911593 |
| | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification | Q75301236 |
| | Osteoprotegerin deficiency and juvenile Paget's disease | Q78515359 |
| | Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts | Q78955391 |
| | Bacterial-responsive B lymphocytes induce periodontal bone resorption | Q81645835 |
| | Role of RANKL inhibition in osteoporosis | Q21195417 |
| | Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review | Q22242702 |
| | Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals | Q22242705 |
| | Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations | Q24310432 |
| | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| | TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 |
| | A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 |
| | Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 |
| | Aging, inflammation, and HIV infection | Q26865415 |
| | HIV: inflammation and bone | Q27010898 |
| | Bone versus immune system | Q28140389 |
| | Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab | Q28265584 |
| | Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity | Q28281515 |
| | Stimulation of B-cell progenitors by cloned murine interleukin-7 | Q28294062 |
| | Denosumab in postmenopausal women with low bone mineral density | Q28298728 |
| | Genetic regulation of osteoclast development and function | Q29617421 |
| | Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 |
| | HIV infection and bone disease | Q30249771 |
| | The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. | Q33823576 |
| | Increased risk of fragility fractures among HIV infected compared to uninfected male veterans | Q33832012 |
| | Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats | Q34068440 |
| | Minireview: the OPG/RANKL/RANK system | Q34102256 |
| | How B cells influence bone biology in health and disease | Q34137037 |
| | B cell development pathways | Q34178187 |
| | Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow | Q34183981 |
| | Involvement of T-lymphocytes in periodontal disease and in direct and indirect induction of bone resorption | Q34246960 |
| | Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 |
| | Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond | Q34366449 |
| | Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro | Q34459310 |
| | Periodontal diseases. | Q34468885 |
| | Microenvironmental niches in the bone marrow required for B-cell development | Q34496406 |
| | Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection | Q34506677 |
| | B-cell targeting in rheumatoid arthritis and other autoimmune diseases | Q34514813 |
| | B cells in HIV infection and disease | Q34605780 |
| | Bone disease in HIV infection: a practical review and recommendations for HIV care providers | Q35019051 |
| | Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions | Q35088160 |
| | T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion | Q35179608 |
| | B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease | Q35222008 |
| | Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis | Q35249619 |
| | Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis | Q35350935 |
| | Aging with HIV vs. HIV seroconversion at older age: a diverse population with distinct comorbidity profiles | Q35393050 |
| | Osteoimmunology: interactions of the immune and skeletal systems | Q35727803 |
| | B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo | Q35804512 |
| | Future challenges for clinical care of an ageing population infected with HIV: a modelling study | Q35925654 |
| | The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling | Q35961678 |
| | The role of RANK ligand/osteoprotegerin in rheumatoid arthritis | Q36111285 |
| | Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss | Q36216058 |
| | Osteoblasts and osteoclasts in bone remodeling and inflammation | Q36230480 |
| | Immune response: the key to bone resorption in periodontal disease | Q36309235 |
| | Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis | Q36368706 |
| | Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency | Q36566505 |
| | B cell depletion therapy in autoimmune diseases | Q36664171 |
| | HIV and bone metabolism | Q36671233 |
| | Immunology of Osteoporosis: A Mini-Review | Q36766801 |
| | Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals | Q36851936 |
| | Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system | Q36938343 |
| | Osteoblastic regulation of B lymphopoiesis is mediated by Gs{alpha}-dependent signaling pathways | Q36964283 |
| | Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone | Q37202226 |
| | Inflammation and bone loss in periodontal disease | Q37232619 |
| | The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis | Q37287589 |
| | Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection | Q37344527 |
| | Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease | Q37390635 |
| | Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets | Q37436035 |
| | Osteoimmunology and the effects of the immune system on bone | Q37626412 |
| | B cells as under-appreciated mediators of non-auto-immune inflammatory disease | Q37728724 |
| | RANK ligand: effects of inhibition. | Q37738754 |
| | Do RANKL inhibitors (denosumab) affect inflammation and immunity? | Q37767159 |
| | Regulation of bone by the adaptive immune system in arthritis | Q37884121 |
| | New developments in osteoimmunology | Q38052462 |
| | Bone health and human immunodeficiency virus infection | Q38095828 |
| | The effects of untreated and treated HIV infection on bone disease | Q38165037 |
| | Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial | Q38498967 |
| | Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function | Q38525468 |
| | Physiological and pathophysiological bone turnover - role of the immune system | Q38867785 |
| | Osteoprotegerin concentrations relate independently to established cardiovascular disease in rheumatoid arthritis. | Q39104753 |
| | Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 |
| | Circulating osteoprotegerin levels are elevated in rheumatoid arthritis: a systematic review and meta-analysis. | Q39429775 |
| | Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis | Q39653219 |
| | Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis | Q40655784 |
| | OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. | Q40991620 |
| | Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial | Q41489196 |
| | Bone alterations associated with HIV. | Q42203594 |
| | Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. | Q42694082 |
| | The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 |
| | Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease | Q43865169 |
| | The presence of local and circulating autoreactive B cells in patients with advanced periodontitis | Q43967409 |
| | B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice | Q44212443 |
| | Regulatory effects of osteoprotegerin on cellular and humoral immune responses | Q44707640 |
| | Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia | Q44786963 |
| | Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis | Q44895972 |
| | Development and function of murine B cells lacking RANK. | Q45766850 |
| | A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 |
| | Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis | Q46178905 |
| | Osteoprotegerin deficiency and juvenile Paget's disease | Q48292818 |
| | Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). | Q51767101 |
| P304 | page(s) | 1851 | |
| P577 | publication date | 2017-12-22 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Beyond Antibodies: B Cells and the OPG/RANK-RANKL Pathway in Health, Non-HIV Disease and HIV-Induced Bone Loss | |
| P478 | volume | 8 | |